Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Inventory Average (2021 - 2025)

Apellis Pharmaceuticals has reported Inventory Average over the past 5 years, most recently at $132.7 million for Q4 2025.

  • Quarterly results put Inventory Average at $132.7 million for Q4 2025, up 31.07% from a year ago — trailing twelve months through Dec 2025 was $132.7 million (up 31.07% YoY), and the annual figure for FY2025 was $112.0 million, down 1.67%.
  • Inventory Average for Q4 2025 was $132.7 million at Apellis Pharmaceuticals, up from $121.9 million in the prior quarter.
  • Over the last five years, Inventory Average for APLS hit a ceiling of $157.0 million in Q2 2024 and a floor of $2.7 million in Q3 2021.
  • Median Inventory Average over the past 5 years was $97.6 million (2023), compared with a mean of $88.6 million.
  • Biggest five-year swings in Inventory Average: skyrocketed 1900.81% in 2022 and later crashed 46.73% in 2025.
  • Apellis Pharmaceuticals' Inventory Average stood at $9.0 million in 2021, then surged by 709.81% to $72.7 million in 2022, then soared by 68.36% to $122.5 million in 2023, then decreased by 17.33% to $101.2 million in 2024, then skyrocketed by 31.07% to $132.7 million in 2025.
  • The last three reported values for Inventory Average were $132.7 million (Q4 2025), $121.9 million (Q3 2025), and $101.7 million (Q2 2025) per Business Quant data.